A Kuwait-linked study of weight recurrence after sleeve gastrectomy helps explain why surgery and medication belong within a longer conversation about treatment.
An obesity operation is a significant medical intervention, but it does not necessarily mark the end of treatment. A study involving Kuwait University surgeon Mohammad Jamal examines the question that follows when some of the lost weight returns: how should care continue after sleeve gastrectomy?
The research, published in Obesity Surgery in April 2024, looked at patients receiving semaglutide or tirzepatide for weight recurrence after the procedure. It places a Kuwaiti research contribution within a wider change in how obesity is understood, with medication, surgery and continuing support considered across the course of a chronic condition.
Jamal is listed as a professor in Kuwait University’s surgery department and the paper’s corresponding author. The significance of the work is not a contest between two forms of treatment. It is the recognition that a patient’s needs can change after an operation, and that the next clinical decision deserves evidence of its own.
What the study actually examined
The retrospective cohort study included 115 patients who had undergone sleeve gastrectomy. Seventy received semaglutide for weight recurrence and 45 received tirzepatide. At six months, average weight loss from the start of medication was 10.3% and 15.5%, respectively. The authors reported no severe adverse events in the cohort.
These are short-term findings from a specific group, not a promise of what every patient will achieve. The study was observational rather than a randomised comparison. Its authors called for longer follow-up to assess durability and highlighted both the likelihood of weight regain after stopping medication and the potential constraint of treatment costs.
The distinction matters to a general reader. A percentage from a research paper describes the people observed, the treatment received and the period measured. It does not settle which treatment an individual should receive. What the study establishes is a relevant clinical question and an initial body of evidence about treating recurrence after an earlier intervention.
A chronic condition changes the timeline
The World Health Organization describes obesity as a chronic disease shaped by interactions between biological, behavioural, social and environmental factors. That definition changes the language around follow-up. Returning for treatment is part of managing a condition over time, rather than proof that the original intervention or the patient has failed.
It also changes what a useful public discussion should include. A before-and-after photograph records two moments. Long-term care concerns what happens between and beyond those moments: changes in health, the suitability of further treatment and the continuing relationship with a clinical team. Those questions can be harder to communicate than an initial result, but they are central to understanding the treatment journey.
For researchers, recurrence creates a distinct population to study. People who have previously undergone surgery cannot simply be treated as interchangeable with people who have never had an operation. Their treatment history matters when interpreting subsequent outcomes, which is why the population selected for Jamal and his colleagues’ paper is important.
Surgery and medication in the same conversation
The 2022 ASMBS and IFSO statement updated international guidance on metabolic and bariatric surgery after three decades of change in evidence and practice. Its recommendations place surgery within the management of obesity and associated conditions, with assessment extending beyond a simple desire to lose weight.
The societies’ patient guidance also emphasises specialist experience and multidisciplinary follow-up. The team can include professionals working in nutrition, physical activity and mental health. These are international recommendations, rather than a statement of a particular Kuwaiti hospital’s eligibility rules or insurance arrangements.
Together, the guidance and the Kuwait-linked study offer a more useful framework than treating surgery and newer medicines as competing headlines. Each is an intervention whose role depends on a clinical assessment. A person may need one form of care at a particular stage and further treatment later. The important question is how those decisions fit together over time.
The research also illustrates the importance of the starting measurement. Its reported percentages describe weight change after medication began in patients who had already undergone surgery. They should not be added to an earlier surgical result or read as the total effect of both treatments. Keeping that reference point clear makes the figures intelligible and avoids turning a carefully defined observation into an exaggerated claim about the entire treatment journey.
The next evidence is longer-term evidence
Six-month results are valuable because they indicate what happened during an observed period. They leave other questions open, including what happens over subsequent years, how consistently treatment can be maintained and how outcomes differ across patient groups. A longer timeline can alter the interpretation of an initially encouraging result without making the earlier research meaningless.
Cost belongs in that discussion because a continuing therapy is also a continuing commitment. A study can identify that issue without demonstrating what every household, insurer or health service will pay. Local reporting should retain the distinction between recognising a potential barrier and claiming to have measured its size in Kuwait.
For the public, the practical contribution of this research is a fuller understanding of what obesity care involves. An operation may be one major stage, followed by new decisions that require evidence, monitoring and an individual plan. Jamal’s work brings attention to that less visible period, where the question is no longer simply what treatment starts the journey, but what care is needed to sustain it.
